Yet how will our system contemplate funding high-cost therapies that deliver potentially curative benefits over such a wide range of years - from 5 to 75 years. …
New CAR-T data once again highlights the evaluation challenge
June 5, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Clinical trials: Competition across countries and companies
December 13, 2019 - - Latest News -
High in fees low on performance measures
December 13, 2019 - - Latest News -
Deborah Monk: Recollections from APMA to Medicines Australia
December 13, 2019 - - Latest News -
Novartis launches Innovation Prize with a focus on MS
December 13, 2019 - - Latest News -
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News